Cyclic adenosine monophosphate-elevating agents inhibit amyloid-beta internalization and neurotoxicity:their action in Alzheimer's disease prevention  

作　　者：Rayudu Gopalakrishna Andrew Oh Narayan R.Bhat William J.Mack 

机构地区：[1]Department of Integrative Anatomical Sciences,Keck School of Medicine,University of Southern California,Los Angeles,CA,USA [2]Department of Neurological Surgery,Keck School of Medicine,University of Southern California,Los Angeles,CA,USA [3]Department of Neuroscience,Medical University of South Carolina,Charleston,SC,USA

出　　处：《Neural Regeneration Research》2023年第12期2675-2676,共2页中国神经再生研究（英文版）

基　　金：NIH grants,NINDS R21 NS116720 and NINDS/NIA RF1 NS130681(to RG and WJM);NIA R21 AG059422(to NRB)。

摘　　要：Recently,we have found that various intracellular cyclic adenosine monophosphate(cAMP)-e leva ting agents,both pharmacological(dibutyryl-cAMP,forskolin,and rolipram)and physiological(pituitary adenylate cyclase-activating polypeptide),decrease cell-surface levels of 67-kDa laminin receptor(67LR)and cellular prion protein(PrP~C).

关 键 词：action PREVENTION Cyclic 

分 类 号：R749.16[医药卫生—神经病学与精神病学]